Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction Patients in Convalescent Period.
Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells
(hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological
function of convalescent period.